Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

Just days af­ter Retrophin shed its last ties to founder Mar­tin Shkre­li, the biotech is re­port­ing that the lead drug he co-in­vent­ed flopped in a piv­otal tri­al. Fos­met­pan­tote­nate flunked both the pri­ma­ry and key sec­ondary end­points in a place­bo-con­trolled tri­al for a rare dis­ease called pan­tothen­ate ki­nase-as­so­ci­at­ed neu­rode­gen­er­a­tion, or PKAN.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER